BioWorld Asia

Jan. 7, 2009

View Archived Issues

Genmab Shares Slide on Interim Zalutumumab Data

Shares in Genmab A/S were off by more than 7 percent during trading Tuesday following an interim update on a Phase III pivotal study of zalutumumab (HuMax-EGFr) in head and neck cancer. (BioWorld International) Read More

UK/U.S. Program Mapping Chemo Response to Cancers

Read More

Hair Loss Gene has Serendipitous Message for Genetic Sleuths

Read More

UK's Stem Cell Proponents Meeting to Discuss Future

Read More

Small EU Biofirms Benefit from Special Assistance

Read More

Cytos Shares Surge on Pfizer Deal Commitment

Read More

Cellectis Terminates genOway's Homologous Recombination Deal

Read More

Other News To Note

Read More